Nohria co-founded Vidara Therapeutics in 2011 and served as its President and Chief Medical Officer until the company’s sale to Horizon Therapeutics in 2014. Nohria is a board-certified neurologist with special qualification in child neurology. He is an experienced biotechnology entrepreneur and drug developer with a track record of success in the pharmaceutical and biotechnology sector. Nohria currently serves as Chairman of the Board for Saol Therapeutics and Sebela Pharmaceuticals. Paul holds degrees in Civil Engineering and Business Systems, INSEAD Leadership development certificates and a Master of Business Administration degree from UCD Michael Smurfit Business School. Prior to Astellas, Paul held senior roles at SAP and Mondi Paper. Paul served on the leadership team of Astellas Pharma's European Pharmaceutical Technology Division, heading up the strategic business planning department developing a highly-successful, multi-cultural team responsible for developing strategic plans and realizing value creating projects across the globe. His background includes 15 years of experience in global supply chain optimization, strategic planning and project leadership in both the consumer goods and pharmaceutical industries. Following the divestment of the hyperimmune portfolios, he has been involved in ensuring the portfolios are transitioned smoothly to the acquiring parties whilst supporting the organizational transformation to focus on the clinical programs. This included including building teams with capabilities to embed acquired hyperimmune product portfolios, establishing a global sales strategy and office in the MENA territory and identifying a new manufacturing partner for long term product manufacturing stability. In 2018, he was made responsible for the international sales and market expansion for the hyperimmune portfolio acquired in 20. Paul joined Saol in 2017 as Vice President of Supply Chain and General Manager of Saol Therapeutics Research Limited, Ireland. Dave has been granted 10 US patents, multiple international patents and has pending patent applications in the fields of pharmaceuticals, drug delivery, medical devices and health technology. He completed his post-graduate studies at Stanford University and has performed research at Harvard Medical School and the Broad Institute. His overall experience in the industry is based on a balance of commercial leadership roles and those which have required technical expertise in the areas of product development, manufacturing scale-up, finance and CMC.ĭave holds a Bachelor of Science degree in Engineering from Northwestern University, as well as Master of Science and Master of Business Administration degrees from the Massachusetts Institute of Technology. As Vice President of Commercial Operations at Corcept, he was instrumental in the early turnaround of the Korlym® franchise, which has since continued to grow at a rapid pace. Prior to Saol, Dave held a number of roles with consistently growing responsibility at both Genentech and Corcept Therapeutics. These successes ultimately led to the creation of a late-stage pipeline that included the approval of LYVISPAH® in 2021 and the sale of the Commercial programs that have accelerated Saol’s investment in SL-1002 in pain related to osteoarthritis of the knee, spasticity, and SL-1009 in rare diseases and oncology. In his role, he has been instrumental in the company strategy that resulted in more than $100M in aggregate financings and subsequent divestitures to support the funding needed to initiate new product development. Dave has been the CEO of Saol Therapeutics since 2016.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |